Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

FRX.TO Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Fennec Pharmaceuticals Inc.TSX: FRX.TO

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables dips below year-ago levels

Q1 FY2026 accounts payables of $1.64M fell 19.5% year over year, behind the +1180.7% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -4.7% a year.

Context

  • Accounts payables amounted to 3.1% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -19.5% toward the trailing-twelve-month pace of +1180.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.64M+230.9% QoQ
Last fiscal yearDec 2025
$1.39M+359.6% YoY
LTMMar 2026
$973.33K+1180.7% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.5%——
1 year+359.6%——
3-year CAGR-4.7%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
1.39M USD
Year-over-year change
+359.6%

Accounts Payables vs competitors

How FRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1180.7% is the highest of 6, against a peer median of -22.4%.
  • Accounts payables amounts to 1.9% of revenue for FRX.TO, versus a peer median of 1.4%.
FRX.TO Competitors
Accounts Payables for FRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DR.TOMedical Facilities CorporationLTM Mar 2026$4.49M USD+349.5%-8.9%1.5%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$4.35M CAD-71.9%—1.4%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$3.31M USD+279.8%+22.0%—
TSND.TOTerrAscend Corp.LTM Mar 2026$3.14M USD-22.4%-33.7%1.2%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$973.33K USD+1180.7%-4.7%1.9%
PRN.TOProfound Medical Corp.LTM Mar 2026$379.28K USD-77.5%—2.0%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$0 CAD——0.0%
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$0 CAD———
Peer median (excluding FRX.TO) —-22.4%-8.9%1.4%

Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.35M)(23.71M)(16.05M)(436K)(9.74M)
Depreciation & Amortization000800K103K
Deferred Income Tax00000
Stock-Based Compensation4.02M4.22M5.35M5.06M7.03M
Change in Working Capital(932K)1.1M(6.78M)16.94M(12.04M)
Accounts Receivables0(1.55M)(7.27M)(7.87M)(12.44M)
Inventory0(576K)(1.58M)579K(1.28M)
Accounts Payables(794K)1.61M1.39M(537K)1.39M
Other Working Capital(138K)1.61M683K24.77M282K
Other Non-Cash Items307K466K326K4.61M(26.45K)
Operating Cash Flow(14.22M)(18.06M)(17.14M)26.98M(14.67M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment5M19.94M5M(13M)(19.82M)
Common Stock Issued000045.01M
Common Stock Repurchased0(194K)(78K)(176K)0
Dividends Paid00000
Other Financing Activities(22K)797K1.64M(439K)(190.27K)
Financing Cash Flow4.98M20.73M6.64M(13.62M)25.01M
Effect of Forex Changes0000(1.5M)
Net Change in Cash(9.24M)2.67M(10.51M)13.37M8.83M
Free Cash Flow(14.22M)(18.06M)(17.14M)26.98M(14.67M)

Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$19.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.